Skip to main content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Clinical Pathology 1/2017

Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma

BMC Clinical Pathology > Ausgabe 1/2017
Mohamed Reda El Ochi, Mohamed Oukabli, Elarbi Bouaiti, Hafsa Chahdi, Adil Boudhas, Mohamed Allaoui, Ahmed Ameur, Mohamed Abbar, Abderrahmane Al Bouzidi
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12907-017-0046-z) contains supplementary material, which is available to authorized users.



Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.


103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.


HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (p = 0.003) and pathological stage (p = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (P = 0.04).


HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.
Additional file 1: DATA EXCEL. data generated/analysed during the study. (XLSX 13 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Clinical Pathology 1/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

14.03.2019 | Originalien | Ausgabe 2/2019

Medikamentennachweise bei bayerischen Altenheimbewohnern – eine rechtsmedizinische Analyse

Erste Ergebnisse aus Screeninguntersuchungen an Urinproben

07.03.2019 | Mammakarzinom | CME | Ausgabe 2/2019

Update der S3-Leitlinie Mammakarzinom

Was gibt es Neues für Pathologen?

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Neuropathologie der Medulloblastome und anderer embryonaler Tumoren des ZNS

Präzisierung der Diagnostik durch Integration genetischer Marker